JULIANA FOLLONI FERNANDES
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
11 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 11
conferenceObject Hospital Length of Stay and Impact of Readmission in the First 100 Days of Allogeneic Stem Cell Transplantation: Comparison among Alternative Donor in Pediatric and Adult Population(2018) KERBAUY, Mariana Nassif; KERBAUY, Lucila Nassif; ESTEVES, Iracema; ROCHA, Juliana DallAgnol; STANZIONE, Renata Leati; RODRIGUES, Morgani; FERNANDES, Juliana Folloni; KUTNER, Jose Mauro; SOBRINHO, Jairo J. N.; MANTOVANI, Luiz Fernando Alves Lima; KERBAUY, Fabio R.; RIBEIRO, Andreza Feitosa; HAMERSCHLAK, Nelson- Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease in a Single Institution in Brazil. Reproducing Good Results with a Reduced Toxicity Regimen(2017) FERNANDES, Juliana Folloni; MANTOVANI, Luiz Fernando Alves Lima; VENANCIO, Angela Mandelli; DORNA, Mayra; PASTORINO, Antonio Carlos; VASCONCELOS, Dewton; NETO, Antonio Condino; MOURA, Ana Carla Augusto; COLLASSANTI, Maria Dulce; ZANICHELLI, Maria Aparecida; CARNEIRO-SAMPAIO, Magda; ROCHA, Vanderson G.; ODONE FILHO, Vicente
- Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases(2020) FERNANDES, Juliana Folloni; NICHELE, Samantha; ARCURI, Leonardo Javier; RIBEIRO, Lisandro; ZAMPERLINI-NETTO, Gabriele; LOTH, Gisele; RODRIGUES, Ana Luiza Melo; KUWAHARA, Cilmara; KOLISKI, Adriana; TRENNEPOHL, Joanna; GARCIA, Julia Lopes; DAUDT, Liane Esteves; SEBER, Adriana; GOMES, Alessandra Araujo; FASTH, Anders; PASQUINI, Ricardo; HAMERSCHLAK, Nelson; ROCHA, Vanderson; BONFIM, CarmemAllogeneic hematopoietic stem cell transplantation (HCT) can cure primary immunodeficiency diseases (PID). When a HLA-matched donor is not available, a haploidentical family donor may be considered. The use of T cell-replete haploidentical HCT with post-transplantation cyclophosphamide (haplo-PTCy) in children with PID has been reported in few case series. A donor is usually readily available, and haplo-PTCy can be used in urgent cases. We studied the outcomes of 73 patients with PID who underwent haplo-PTCy, including 55 patients who did so as a first transplantation and 18 who did so as a salvage transplantation after graft failure of previous HCT. The median patient age was 1.6 years. Most of the children were male (n = 54) and had active infection at the time of transplantation (n = 50); 10 children had severe organ damage. The diagnosis was severe combined immunodeficiency (SCID) in 34 patients and non-SCID in 39 (Wiskott-Aldrich syndrome; n = 14; chronic granulomatous disease, n = 10; other PID, n = 15). The median duration of follow-up of survivors was 2 years. The cumulative incidence of neutrophil recovery was 88% in the SCID group and 84% in non-SCID group and was 81% for first transplantations and 83% after a salvage graft. At 100 days, the cumulative incidence of acute GVHD grade II-IV and III-IV was 33% and 14%, respectively. The majority of patients reached 200/mu L CD4(+) and 1000/mu L CD3(+) cell counts between 3 and 6 months. The estimated 2-year overall survival was 66%; it was 64% for SCID patients and 65% for non-SCID patients and 63% for first HCT and 77% for salvage transplantations. Twenty-five patients died, most of them due to infection early after transplantation (before 100 days). In conclusion, haplo-PTCy is a feasible procedure, can cure two-thirds of children with PID, and can be used as rescue treatment for previous graft failure. (C) 2020 American Society for Transplantation and Cellular Therapy.
conferenceObject T-Cell Replete Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide (PTCy) for Pediatric Patients with Primary Immunodeficiencies (PID) - a Survey of the Pediatric Transplantation Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO)(2020) FERNANDES, Juliana Folloni; NICHELE, Samantha; RIBEIRO, Lisandro; LOTH, Gisele; NETTO, Gabriele Zamperlini; SEBER, Adriana; DAUDT, Liane Esteves; GOMES, Alessandra; KOLISKI, Adriana; RODRIGUES, Ana Luiza Melo; ARCURI, Leonardo Javier; HAMERSCHLAK, Nelson; BONFIM, CarmemconferenceObject Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Severe Aplastic Anemia(2020) BONFIM, Carmem; ARCURI, Leonardo Javier; NABHAN, Samir; SEBER, Adriana; NICHELE, Samantha; FUNKE, Vaneuza Araujo Moreira; FERNANDES, Juliana Folloni; DAUDT, Liane Esteves; DARRIGO JR., Luiz Guilherme; RODRIGUES, Ana Luiza Melo; CUNHA, Renato Luiz Guerino; ARRAIS, Celso; RIBEIRO, Andreza Feitosa; ATTA, Elias; OLIVEIRA, Jose Salvador Rodrigues; PAZ, Alessandra; CALIXTO, Rodolfo Froes; GOMES, Alessandra; ARAUJO, Carlos Eduardo Sa; SR., Vergilio A. R. Colturato; FLOWERS, Mary E. D.; PASQUINI, Ricardo- Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia(2020) ARCURI, Leonardo Javier; NABHAN, Samir Kanaan; CUNHA, Renato; NICHELE, Samantha; RIBEIRO, Andreza Alice Feitosa; FERNANDES, Juliana Folloni; DAUDT, Liane Esteves; RODRIGUES, Ana Luiza Melo; ARRAIS-RODRIGUES, Celso; SEBER, Adriana; ATTA, Elias Hallack; OLIVEIRA, Jose Salvador Rodrigues de; FUNKE, Vaneuza Araujo Moreira; LOTH, Gisele; DARRIGO JUNIOR, Luiz Guilherme; PAZ, Alessandra; CALIXTO, Rodolfo Froes; GOMES, Alessandra Araujo; ARAUJO, Carlos Eduardo Sa; COLTURATO, Vergilio; SIMOES, Belinda Pinto; HAMERSCHLAK, Nelson; FLOWERS, Mary Evelyn; PASQUINI, Ricardo; ROCHA, Vanderson; BONFIM, CarmemSevere aplastic anemia (SAA) is a life-threatening disease that can be cured with allogeneic cell transplantation (HCT). Haploidentical donor transplantation with post-transplantation cyclophosphamide (haplo-PTCy) is an option for patients lacking an HLA-matched donor. We analyzed 87 patients who underwent haplo-PTCy between 2010 and 2019. The median patient age was 14 years (range, 1 to 69 years), most were heavily transfused, and all received previous immunosuppression (25% without antithymocyte globulin). Almost two-thirds (63%) received standard fludarabine (Flu)/cyclophosphamide (Cy) 29/total body irradiation (TBI) 200 cGy conditioning, and the remaining patients received an augmented conditioning: Flu/Cy29/TBI 300-400 (16%), Flu/Cy50/TBI 200 (10%), or Flu/Cy50/TBI 400 (10%). All patients received PTCy-based graft-versus-host disease (GVHD) prophylaxis. Most grafts (93%) were bone marrow (BM). The median duration of follow-up was 2 years and 2 months. The median time to neutrophil recovery was 17 days. Primary graft failure occurred in 15% of the patients, and secondary or poor graft function occurred in 5%. The incidences of grade II-IV acute GVHD was 14%, and that of chronic GVHD was 9%. Two-year overall survival and event-free survival (EFS) were 79% and 70%, respectively. EFS was higher for patients who received augmented Flu/Cy/TBI (hazard ratio [HR], .28; P = .02), and those who received higher BM CD34 cell doses (3.2 10E6/kg) (HR, .29; P = .004). The presence of donor-specific antibodies before HSCT was associated with lower EFS (HR, 3.92; P = .01). Graft failure (HR, 7.20; P < .0001) was associated with an elevated risk of death. Cytomegalovirus reactivation was frequent (62%). Haploidentical HCT for SAA is a feasible procedure; outcomes are improved with augmented conditioning regimens and BM grafts with higher CD34 cell doses. (C) 2020 American Society for Transplantation and Cellular Therapy.
conferenceObject Hematopoietic Stem Cell Transplantation in Primary Immunodeficiencies in Brazil-a Survey of the Working Group on Paediatric Transplantation of the Brazilian Society of Bone Marrow Transplantation(2015) FERNANDES, Juliana Folloni; SEBER, Adriana; DAUDT, Liane Esteves; RIBEIRO, Lisandro; ZECCHIN, Victor; MAUAD, Marcos A.; DARRIGO JR., Luiz Guilherme; VIEIRA, Ana Karine; GREGIANIN, Lauro; SOUSA, Adriana Martins; SANTINI, Adriana; TAVARES, Rita; NICHELE, Samantha; KOLISKI, Adriana; BOUZAS, Luis Fernando S.; HAMERSCHLAK, Nelson; BONFIM, CarmemconferenceObject Outcomes after Hematopoietic Cell Transplantation (HCT) in Brazil for Children and Adolescents with Non-Malignant Diseases: A Multicenter Study on Behalf on the Brazil-Seattle Consortium Study Group(2018) BONFIM, Carmem; FRANCO, Simone; COLTURATO, Vergilio A. R.; FERNANDES, Juliana Folloni; ZECCHIN, Victor; SEBER, Adriana; DARRIGO, Luiz Guilherme; DAUDT, Liane Esteves; ARCURI, Leonardo Javier; FLOWERS, Mary E.conferenceObject Data Manager in a Bone Marrow Transplant Team in Brazil: Training, Certifications, International Connections and Dissemination(2020) SILVA, Cinthya Correa; VOGEL, Cristina; WAISBECK, Tania Michele; RIBEIRO, Andreza Feitosa; SODRE, Lidiane Soares; KONDO, Andrea; TORRES, Margareth; EDUARDO, Fernanda de Paula; BEZINELLI, Leticia Mello; FERNANDES, Juliana Folloni; HAMERSCHLAK, NelsonconferenceObject Population Pharmacokinetic Study of a Test Dose Busulfan Patients Undergoing Hematopoietic Stem Cell Transplantation(2013) NOGUEIRA, Iracema Esteves; FERNANDES, Juliana; SUGAWARA, Eduardo K.; OLIVEIRA, Jose Salvador de; GOUVEIA, Roseane; RODRIGUES, Morgani; BARROS, Daniele Porto; DINIZ, Mariane Pereira; SANTOS, Fabio P. de Souza; RIBEIRO, Andreza Feitosa; SOBRINHO, Jairo J. N.; NAKASHIMA, Sandra Saemi; LIMA, Marcos de; HAMERSCHLAK, Nelson; KERBAUY, Fabio R.